Fortescue Faces Class Action Over Sexual Harassment Claims at Australian Mining Sites 
Australia Inflation Cools in May, But Core CPI Keeps RBA Rate Hike Risks Alive 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
South Korea Stocks Tumble as AI-Fueled Rally Faces Profit-Taking Pressure 
Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
Asian Stocks Slip as Oil Rebounds Amid Fed Rate Hike Fears 
New Zealand Fast-Tracks Gold Mining as Industry Revival Gains Momentum 
BOJ Hawk Signals Faster Interest Rate Hikes Amid Inflation Risks 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
Malaysia Central Bank Moves to Support Ringgit Amid Foreign Fund Outflows 
Micron Stock Surges on Strong AI Demand, Record Revenue, and Bullish Q4 Forecast 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
Trump Requests $11 Billion More in Farm Aid as Rising Costs Pressure U.S. Farmers 
Japan Signals Preference for Low Interest Rates as BOJ Policy Debate Intensifies 
Celltrion, a South Korean pharmaceutical company, revealed on Thursday, Aug. 12, that it has received emergency approval from the government of Brazil for its COVID-19 antibody treatment.
According to The Korea Herald, Celltrion shared that the Health Regulatory Agency of the said country granted emergency use authorization (EUA) for its Regkirona or CT-P59, which is a COVID-19 treatment. It was said that the agency made the decision based on the results of the drug’s clinical tests for all three phases.
Celltrion added that the Brazilian health agency also looked into their preclinical studies that show the efficacy of the treatment against COVID-19 variants. Once it is made available in Brazil, Regkirona will be utilized for the treatment of adult patients who are at higher risk from COVID-19 and experiencing both mild and severe symptoms.
Korea Biomedical Review reported that adults aged 65 or older with mild and moderate symptoms would also be treated with Celltrion’s antibody drug. With the high number of daily coronavirus cases in Brazil today, Celltrion said it will deliver Rekirona to the country as fast as it could to help treat the patients.
In the COVID-19 world statistics on Worldometer, Brazil has more than 20 million cases of coronavirus infection and more than 560,000 deaths. With the spread of the more contagious Delta variant, the country is recording daily cases of around 10,000 to 30,000.
“Based on the safety and efficacy proven through large-scale global clinical data of Regkirona, the company has obtained emergency use approval from the Brazilian health authorities,” a Celltrion official stated. “We will do our best to contribute to preventing the spread of Covid-19 by supplying Regkirona early to Brazil, where the number of confirmed cases has recently rapidly increased to 30,000 a day due to the spread of the Delta variant.”
Celltrion declared that its Rekirona antibody treatment drug could reduce the risk of the coronavirus infection from progressing to a severe stage. The pharmaceutical firm further said that it could lessen the recovery time as well. Meanwhile, with the Brazilian EUA, Celltrion is planning to submit an application for similar authorization in the U.S.
